Alpesib 150mg Tablet (Alpelisib)

Alpesib 150mg Tablet is a prescription-based anticancer medicine used in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer that has specific PIK3CA mutations. The active ingredient of the Alpesib is alpelisib, which belongs to the drug class of phosphatidylinositol-3-kinase (PI3K) inhibitors. This drug works by blocking the function of the PI3K-alpha pathway, which can become overactive in cancer cells. This helps prevent the growth and spread of the cancer cells. Alpelisib 150mg Tablet is usually given in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.

The tablet must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Alpelisib 150mg tablet depend on the patient's condition and response to treatment. It is taken with food at the same time every day. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include increased blood sugar levels, diarrhea, nausea, decreased appetite, vomiting, tiredness, rash, itching, and weight loss. A few patients can undergo severe side effects, including severe high blood sugar, severe skin reactions, lung inflammation, and severe diarrhea. Most of the Alpelisib 150mg Tablet side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine may harm an unborn baby and should not be used during pregnancy. Women who can become pregnant should use effective contraception during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Alpelisib 150mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

The human body shows undesired symptoms after taking Alpesib 150mg Tablet (Alpelisib). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Alpelisib 150mg Tablet (Alpesib) is a prescription-based anticancer drug that should be administered orally. Dosage and the duration determined as per stage & type of cancer and the patients’ health condition. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.

● Xu, H., Chen, K., Shang, R., Chen, X., Zhang, Y., Song, X., ... & Chen, X. (2021). Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death & Disease, 12(10), 920.
● Armaghani, A. J., & Han, H. S. (2020). Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data. Breast Cancer: Targets and Therapy, 251-258.
● André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.
● Singh, S., Bradford, D., Li, X., Mishra-Kalyani, P. S., Shen, Y. L., Wang, L., ... & Donoghue, M. (2024). FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clinical Cancer Research, 30(1), 23-28.
● André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Juric, D. (2019). Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.